Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute based in Seattle, Washington.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $170M
Founded date: 2017
Investors 4
| Date | Name | Website |
| 09.05.2022 | E&Inve... | eninvestme... |
| 17.08.2023 | Hercules C... | htgc.com |
| 17.02.2022 | RA Capital... | racap.com |
| - | Adjuvant C... | adjuvantca... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.03.2025 | Series B | $110M | - |
| 11.02.2022 | Series A | $60M | - |
Mentions in press and media 8
| Date | Title | Description |
| 18.03.2025 | Curevo's $110 Million Bet on Shingles Vaccine: A Game Changer in Immunization | In the bustling world of biotechnology, Curevo Vaccine has made headlines with its recent $110 million Series B funding round. This infusion of capital is not just a financial boost; it’s a lifeline for a company on the brink of a significa... |
| 18.03.2025 | Curevo: $110 Million (Series B) Raised For Advancing Amezosvatein Shingles | Curevo Vaccine – a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability – announced the closing of a $110 million Series B round to advance the developm... |
| 17.03.2025 | Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine | -- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures -- Former Chair of GSK’s vaccine business... |
| 17.03.2025 | Curevo Raises $110M in Series B Funding | Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $110M in Series B funding. The round was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Ca... |
| 11.02.2022 | Curevo Vaccine Raises $60M in Series A Funding | Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $60M in Series A funding. The round was led by RA Capital Management joined by Adjuvant Capital, Janus Henderson Investors, EN Investment, and founding investor GC Pha... |
| 11.02.2022 | Vaccine startup Curevo takes on pharma giant GSK, raises $60M for trial of shingles shot | Curevo CEO George Simeon. (Curevo Photo) Curevo has raised $60 million to develop a new vaccine for shingles, an often-painful condition caused by reactivation of the chickenpox virus. The new funding will enable the Seattle-based startup t... |
| 11.02.2022 | Green Cross : Curevo Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines | Curevo's lead program is CRV-101, an adjuvanted subunit vaccine for shingles, which has demonstrated robust immunogenicity and tolerability in Phase 1 trials Financing funds the 678-patient Phase 2b head-to-head trial of CRV-101 against Shi... |
| - | Curevo | “https://videos.files.wordpress.com/1c7Vju9e/labsmall.mp4 Creating Next Generation Vaccines for Diseases of Global Importance Learn More Our Strength Creating a new generation of adjuvanted subunit vaccines We've been in business since 2018... |